Nuochengjianhua announced that the phase III registered clinical trial of the self-developed next-generation highly selective oral tyrosine kinase 2 allosteric inhibitor fadeucravacitinib for the treatment of patients with moderate to severe plaque psoriasis has reached the main end. The study results showed that Fadeucravacitinib reached the primary endpoint, was statistically highly significant, and achieved clinically significant improvements. At the same time, several secondary endpoints have also been successfully achieved, showing consistent significant treatment effects in various efficacy evaluation indicators.

Nuochengjianhua announced that the phase III registered clinical trial of the self-developed next-generation highly selective oral tyrosine kinase 2 allosteric inhibitor fadeucravacitinib for the treatment of patients with moderate to severe plaque psoriasis has reached the main end. The study results showed that Fadeucravacitinib reached the primary endpoint, was statistically highly significant, and achieved clinically significant improvements. At the same time, several secondary endpoints have also been successfully achieved, showing consistent significant treatment effects in various efficacy evaluation indicators.